Monoclonal antibodies that inhibit the interaction between PD-1 and PD-L1 block this inhibitory function and have led to improved survival in patients with metastases of cutaneous melanoma, colorectal cancer and non-small cell lung cancer [8–10]. Here, PDCD1 is linked to non-small cell lung carcinoma.